CRNX Crinetics Pharmaceuticals, ...

Nasdaq crinetics.com


$ 41.75 $ -0.74 (-1.75 %)    

Friday, 17-Oct-2025 16:03:25 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 41.57
$ 42.08
$ 40.30 x 10
$ 43.00 x 100
$ 41.07 - $ 42.80
$ 24.10 - $ 62.53
1,509,217
na
2.24B
$ 0.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-13-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-87

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price...

 morgan-stanley-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-77

Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Overweight and raises the pric...

 goldman-sachs-maintains-neutral-on-crinetics-pharmaceuticals-raises-price-target-to-40

Goldman Sachs analyst Richard Law maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Neutral and raises the price ta...

 fda-approves-crinetics-pharmas-first-daily-pill-for-rare-growth-disorder

On Thursday, the U.S.

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 crinetics-pharmaceuticals-blackberry-perpetua-resources-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...

 assessing-crinetics-pharmaceuticals-insights-from-4-financial-analysts

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of...

 jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-143

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Market Outperform and rai...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 baird-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-62

Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Outperform and raises the price target...

 crinetics-pharmaceuticals-receives-fda-approval-for-palsonify-palsonify-is-expected-to-be-available-in-the-us-in-early-october

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) today announced that the U.S.

 jp-morgan-maintains-overweight-on-crinetics-pharmaceuticals-lowers-price-target-to-52

JP Morgan analyst Jessica Fye maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and lowers the price targe...

 jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-lowers-price-target-to-86

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowe...

 crinetics-pharmaceuticals-announces-palsonify-nda-on-track-with-september-25-2025-pdufa-date-has-12b-in-cash-and-investments-as-of-june-30-2025-anticipated-to-provide-runway-into-2029

-SEC Filing

 crinetics-pharmaceuticals-q2-eps-123-misses-108-estimate-sales-1031m-beat-155000k-estimate

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.23) per share which missed the analyst consensus estim...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION